Delayed onset of pseudotumor cerebri syndrome 7 years after starting human recombinant growth hormone treatment

To report a case of pseudotumor cerebri (PTC) following treatment with human recombinant growth hormone (GH). A 42-year-old man who developed pseudotumor cerebri 7 years after starting human recombinant GH treatment is presented. The patient's medical history was significant for hypophyseal dwa...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2006-01, Vol.16 (1), p.178-180
Main Authors: Vischi, A, Guerriero, S, Giancipoli, G, Lorusso, V, Sborgia, G
Format: Article
Language:English
Subjects:
Adult
Growth Hormone - adverse effects
Humans
Male
Papilledema - chemically induced
Papilledema - diagnosis
Pseudotumor Cerebri - chemically induced
Pseudotumor Cerebri - diagnosis
Syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To report a case of pseudotumor cerebri (PTC) following treatment with human recombinant growth hormone (GH). A 42-year-old man who developed pseudotumor cerebri 7 years after starting human recombinant GH treatment is presented. The patient's medical history was significant for hypophyseal dwarfism with a serious deficit of GH, hypogonadotropic hypogonadism, and hypothyroidism. In 1996 he started taking GH, testosterone, and L-thyroxine. Fundus examination showed disc edema in the left eye. GH was discontinued, and acetazolamide therapy was initiated. At the 3-month follow-up the acuity without correction was patch and the unilateral papilledema had resolved. Pseudotumor cerebri or idiopathic intracranial hypertension is an uncommon and complex disorder. The diagnosis is possible when important criteria symptoms and signs are met. Several conditions and risk factors are associated with PTC. The most recently recognized risk factor is GH therapy.
ISSN:1120-6721
1724-6016
DOI:10.1177/112067210601600131